Sanofi (EURONEXT:SAN) halted amlitel imab for atopic dermatitis over efficacy and safety concerns and won’t seek approval, even as a Phase 2 celiac readout is expected H2 2026; leadership changes with Belen Garijo as CEO and Paulo Fontoura heading R&D signal a strategic pipeline reassessment.
Previous Week Recap
- Sanofi Halts Amlitel Imab; Celiac Study Active: Sanofi (SAN) halted amlitel imab development for atopic dermatitis due to efficacy and safety issues, won’t file for approval. Phase 2 celiac study remains active; readout expected H2 2026.
- Sanofi Names CEO, R&D Head: Sanofi SA Sponsored ADR (SAN) named Belen Garijo CEO and Paulo Fontoura head of R&D during a pipeline review; leadership shifts announced amid company pipeline evaluation affecting strategy.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.